GlassScriptPhysician profile
Ren Yu Zhang
NPI 1902910052
$8,321.65
in general payments reported to CMS, 2019-2025
11 companies · $84.20 in 2025
The $84.20 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $27.67 · 2021: $16.36 · 2022: $49.36 · 2023: $81.87 · 2024: $7,241 · 2025: $84.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,300 · Travel and Lodging: $698 · Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,300.00 |
| Travel and Lodging | $698.25 |
| Food and Beverage | $408.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $6,308.44 | 2024 | Harmonic |
| Medical Device Business Services, INC. | $896.07 | 2024 | Harmonic |
| Intuitive Surgical, INC. | $729.43 | 2019 | |
| Aroa Biosurgery Incorporated | $84.20 | 2025 | |
| Merck Sharp & Dohme LLC | $76.93 | 2019-2022 | |
| Boston Scientific Corporation | $62.41 | 2019-2020 | |
| Novo Nordisk INC | $45.86 | 2023 | |
| Clovis Oncology, INC. | $45.65 | 2019 | |
| La Jolla Pharmaceutical Company | $36.01 | 2023 | Xerava |
| Takeda Pharmaceuticals U.S.A., INC. | $32.80 | 2024 | Gattex |
| Biocomposites INC | $3.85 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ren Yu Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.